Drug class
Methylxanthine bronchodilator; xanthine derivative
Mechanism of action
The exact molecular mechanism is not fully resolved. Doxofylline produces bronchodilation and has been described as modulating phosphodiesterase/cyclic-AMP signalling; unlike theophylline, it has markedly reduced affinity for adenosine receptors and does not show the same adenosine-antagonist profile.
General use cases
- Bronchial asthma
- Chronic obstructive pulmonary disease (COPD) and other obstructive airway conditions where doxofylline is authorised; indication and formulation differ by jurisdiction
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
